Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial-Reference-Cited by-同舟云学术

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Published:2019-01-16 Issue:1 Volume:20 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Lee Myungsun,Mok Jeongha,Kim Deog Kyeom,Shim Tae Sun,Koh Won-Jung,Jeon Doosoo,Lee Taehoon,Lee Seung Heon,Kim Ju Sang,Park Jae Seuk,Lee Ji Yeon,Kim Song Yee,Lee Jae Ho,Jo Kyung-Wook,Jhun Byung Woo,Kang Young Ae,Ahn Joong Hyun,Kim Chang-Ki,Shin Soyoun,Song Taeksun,Shin Sung Jae,Kim Young Ran,Ahn Heejung,Hahn Seokyung,Won Ho Jeong,Jang Ji Yeon,Cho Sang Nae,Yim Jae-Joon

Funder

Korea Centers for Disease Control & Prevention

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-018-3053-1.pdf

Reference37 articles.

1. World Health Organization. Global tuberculosis report 2014. 2014

2. World Health Organization. Global tuberculosis report 2017. 2017

3. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2016. p. 44.

4. Jeon D. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis. 2017;80(4):336–43. https://doi.org/10.4046/trd.2017.0049 Epub 2017 Sep 1.

5. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. 2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments;Clinical Microbiology Reviews;2023-12-20

2. Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes;Annals of the American Thoracic Society;2023-12

3. Long-term results of treatment of patients with newly detected pulmonary tuberculosis;Meditsinskiy sovet = Medical Council;2023-11-17

4. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians;Respiration;2022-12-14

5. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea;The Lancet;2022-10